OR WAIT 15 SECS
© 2020 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2020 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
February 01, 2011
The Promise Of Translational Medicine
Novartis' Gilenya is a step forward in treating Multiple Sclerosis. But generating increased compliance is another story
If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshhot of what's ahead for Big Pharma in the country
Adapting training techniques is necessary to thrive in the fact-changing dynamic of a physician's office
With Francis Collins now calling the shots at NIH, will be be able to deliver on the innovations behind the genome?
Increased efficiency and lower operating costs for both CROs and vendors can be achieved by eliminating activities
To manage through a resource-constrained environment, it is essential to get the most out of procurement planning
What are some of the essential characteristics of the US market? Statistics drawn from the 2011 Statistical Abstract of the US shed some light
The Three Cs could be taxing on FDA resources as the new Congress brings stiffer oversight and leadership revisions to the agency
All this uncertainty at the back end of drug development is a drain on future therapeutic progress against disease. It's a job killer, too.
With the impact of the sales rep in decline, it's time to beef up training for other pharma functions to fill the gap in a competitive marketplace